Nursing EMPOWER: Personalizing Patient Management through Communication and Education on Advanced or Metastatic HR-Positive, HER2-Negative Breast Cancer
Shayma Master Kazmi, MD, RPh
Medical Lead of Advanced Oncology, Oncology/Hematology
Comprehensive Care and Research Center
This online activity is focused on the care of patients with early HR positive, HER2-negative breast cancer.
This CME initiative is designed to meet the educational needs of oncology nurses, nurse practitioners, and other healthcare providers involved in the treatment of patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer.
After completing the CME activity, learners should be better able to:
- Describe the unique mechanism of action that CDK 4/6 inhibition provides as oral oncolytic agents in advanced or metastatic HR+/HER2-negative breast cancer
- Review the role of oral CDK 4/6 inhibitors in the treatment of advanced or metastatic breast cancer
- Explore the side-effect profiles of the CDK 4/6 inhibitors and toxicity management in the management of advanced or metastatic HR+/HER2-negative breast cancer
- Review the oncology nurse’s role in the recognition of breast cancer treatment-related adverse events while optimizing patient medication persistence
- Assess ways in which to communicate more openly with patients in order to encourage their engagement across all aspects of their care
- Evaluate current data for decision aids and shared decision-making in optimizing patient and healthcare-team communication and goal-setting
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this online activity for a maximum of 1.5 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the online activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the care of patients with breast cancer. Credits: 1.5 ANCC Contact Hours
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Dr. Kazmi is a Speakers Bureau member for Merck, Eisai, Takeda, and Lilly. She is also a consultant for Eisai and Takeda.
CME CONTENT REVIEW
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE CONTENT REVIEW
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Lisa Crenshaw, Senior Program Manager for Med Learning Group, has nothing to disclose.
Nicole Longo, DO, FACOI, Medical Director for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this online activity. To receive CME/CNE credit
1. Read the CME/CNE information and faculty disclosures.
2. Participate in the online activity.
3. Submit the evaluation form to Med Learning Group.
You will receive your certification via email within 30 days.
Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at email@example.com
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement
information at http://medlearninggroup.com/privacy‐policy/
RELEASE DATE: March 27, 2019
EXPIRATION DATE: March 27, 2020
Copyright © 2019 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.